Clinical trials: Covid19, Vaccines
Safety Issues
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
The aim of this study is evaluating safety profile of COVID-19 Vaccine in healthy adults aged >18 years in Indonesia.
- Trial name
- NCT05037227
- Where
- Indonesia
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Covid19
Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full…
- Trial name
- VAX-TRES (NCT04930770)
- Testing
- MRNA-1273
- Sponsor
- Maria Joyera Rodríguez
Cancer, Covid-19
Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)
Based on recent data, COVID (COV) vaccination in cancer patients (pts) is strictly recommended. For oncologic pts,2 types of m-RNA vaccines have been approved: BNT162b2 (Pfizer, Biontech) and mRNA-1273 (Moderna, NIAID).
- Conditions
- Cancer, Covid-19, Vaccine Response
- Trial name
- ANTICOV (NCT04878796)
- Testing
- Serum collection, adverse events collection
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Socio Sanitaria Territoriale di Cremona
Coronavirus Disease (COVID-19)
Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
The primary objective of this study is to evaluate the safety and tolerability of V590 versus placebo and to assess the immunogenicity of V590 on Day 28.
- Trial name
- NCT04569786
- Testing
- V590
- Where
- 7 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study are: To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
- Trial name
- VAW00001 (NCT04798027)
- Testing
- SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
SARS-CoV-2 Infection
Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.
An open label, randomized, dose comparison, sequential cohorts study design in healthy volunteers (young adults) is a frequently used design in vaccine Phase 1 studies.
- Trial name
- NCT05385991
- Testing
- ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
- Where
- 6 sites in Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ACM Biolabs
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Immune System Diseases, COVID-19 Vaccine Adverse Reaction
COVID-19 Post-Vaccination Observation
The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis.
- Conditions
- Immune System Diseases, COVID-19 Vaccine Adverse Reaction, Immune System Disorder
- Trial name
- NCT06107348
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Yang I. Pachankis, PhD
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine.
- Trial name
- NCT06255626
- Testing
- CD40.RBDv vaccin (SARS-Cov2 Vaccin)
- Where
- 2 sites in France
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
- Trial name
- NCT05142514
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- Vietnam
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
The present test-negative design study aims to estimate the real-world effectiveness of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 infection and its consequences following a mass vaccination campaign in the…
- Trial name
- NCT05052307
- Testing
- Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, CoronaVac COVID-19 vaccine, ChAdOx1 nCoV-19 Covid-19 Vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 4,574 people
- Sponsor
- Hospital Moinhos de Vento
Covid19, Humoral Acquired Immunodeficiency
Antibody Detection of Vaccine-Induced Secretory Effects
The purpose of this research study is to conduct a prospective longitudinal surveillance research study, enrolling approximately 60 lactating mothers who receive the SARS-CoV-2 vaccine, and then following their clinical and…
- Conditions
- Covid19, Humoral Acquired Immunodeficiency, Coronavirus, SARS-CoV Infection
- Trial name
- ADVISE (NCT04895475)
- Testing
- SARS-CoV-2 vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Covid19
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized
Randomized controlled trial to evaluate safety, immunogenicity and efficacy of three different doses (10, 25 and 50 mcg) of a novel vaccine compared with placebo in adult volunteers previously immunized against Covid-19 with…
- Trial name
- NCT05016934
- Testing
- A vaccine composed of a recombinant S1 antigen
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital do Coracao
SARS-CoV-2
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
Determine safety and tolerability and immungenicity of investigational vaccine ARCT-021 in healthy adult volunteers.
- Trial name
- NCT04480957
- Testing
- ARCT-021 Dose 1, ARCT-021 Dose 2, ARCT-021 Dose 3
- Where
- Singapore
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Coronavirus Infections, Vaccine
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory…
- Conditions
- Coronavirus Infections, Vaccine, Polio
- Trial name
- NCT05083039
- Where
- Russia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Covid19, Vaccine Reaction
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination.
- Trial name
- NCT04922944
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Huntington Memorial Hospital
COVID-19
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster…
- Trial name
- NCT05875701
- Testing
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with…
- Trial name
- COVID-19 (NCT05374954)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- 10 sites in China
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited